Evidence map›Paper›PMID 42505679›Full record

ArticleClinics and practice2026

Effectiveness of Guselkumab for the Treatment of Moderate-to- Severe Psoriasis in Elderly Patients: A Retrospective, Real-World Multicenter Study in the Lazio Region.

Giuseppe P A Gemma, Nicoletta Bernardini, Francesca Paola Sasso, Giacomo Caldarola, Eleonora De Luca, Maria Elisabetta Greco, Viviana Lora, Annamaria Mazzotta, Emanuele Miraglia, Diego Orsini and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinics and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Giuseppe P A GemmaDermatology Clinic, Department of Medical and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0009-0002-0893-1881
Nicoletta BernardiniDermatology Unit, ASL Latina, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100 Latina, Italy.ORCID 0000-0002-6295-3574
Francesca Paola SassoDermatology Clinic, Department of Medical and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy.
Giacomo CaldarolaUOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli-IRCCS, 00168 Rome, Italy.
Eleonora De LucaUOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli-IRCCS, 00168 Rome, Italy.ORCID 0000-0003-3893-2869
Maria Elisabetta GrecoDermatology Clinic, Department of Medical and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0009-0008-5067-8190
Viviana LoraClinical Dermatology Unit, San Gallicano Dermatological Institute IRCCS, 00144 Rome, Italy.
Annamaria MazzottaDermatology Unit, A.O. San Camillo Forlanini, 00151 Rome, Italy.
Emanuele MiragliaClinic of Dermatology, San Sebastiano Hospital, Frascati, 00044 Rome, Italy.
Diego OrsiniDepartmental Faculty of Medicine UniCamillus, "Saint Camillus International University of Health and Medical Sciences", 00131 Rome, Italy.
Gianluca PagnanelliIstituto Dermopatico Dell'immacolata IDI IRCCS, 00167 Rome, Italy.
Antonio Giovanni RichettaDermatology Clinic, Department of Medical and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0002-8755-9178
Nevena SkrozaDermatology Unit, ASL Latina, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100 Latina, Italy.ORCID 0000-0003-4478-5404
Annunziata DattolaDermatology Clinic, Department of Medical and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0001-9504-5882

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGuselkumab, a selective interleukin-23 inhibitor, is effective in moderate-to-severe plaque psoriasis, but real-world long-term data in elderly patients remain limited.

objectiveTo evaluate the long-term effectiveness of guselkumab in elderly patients with moderate-to-severe psoriasis in a real-world setting.

methodsThis retrospective, multicenter study included 102 patients aged 65 years or older treated with guselkumab across seven Italian centers. PASI scores and PASI 75/90/100 responses were assessed as observed cases at weeks 4, 16, 28, and 52, and annually up to 4 years, with last-observation-carried-forward and non-responder imputation as sensitivity analyses. Subgroups by biologic experience and BMI were analyzed.

resultsMean PASI decreased from 12.4 to 0.3 at week 52, remaining low through year 4 (

conclusionsGuselkumab was associated with high and durable PASI improvement in elderly patients, regardless of prior biologic exposure or body weight. The retrospective design and absence of systematic safety data warrant cautious interpretation.

Indexed as

effectivenesselderly patientsguselkumabpsoriasisreal world

Identifiers

PMID42505679
PMCPMC13409236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.